ストックスクリーナーアプリを入手
1.965
0.56%
0.015
前日終値:
$1.95
開ける：
$1.95
24時間の取引高:
2.62M
Relative Volume:
0.37
時価総額：
$404.86M
収益：
$176.23M
当期純損益:
$-257.83M
株価収益率:
-1.3552
EPS:
-1.45
ネットキャッシュフロー:
$-246.00M
1週間 パフォーマンス:
-8.79%
1か月 パフォーマンス:
+114.79%
6か月 パフォーマンス:
+228.26%
1年 パフォーマンス:
+424.61%
1日の値動き範囲:
$1.89
$2.03
1週間の範囲:
$1.82
$2.185
52週間の値動き範囲:
$0.304
$3.179
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
名前
Sangamo Therapeutics Inc
セクター
電話
(510) 970-6000
住所
501 CANAL BLVD., RICHMOND, CA
SGMO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| SGMO | 1.965 | 404.86M | 176.23M | -257.83M | -246.00M | -1.45 |
| VRTX | 449.39 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.14 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 595.48 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.50 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.14 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-04-28 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-02-27 | アップグレード | Wedbush | Neutral → Outperform |
| 2023-01-06 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-06-13 | 再開されました | Wedbush | Neutral |
| 2021-05-04 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-01-07 | 再開されました | Guggenheim | Neutral |
| 2021-01-06 | 開始されました | Stifel | Hold |
| 2020-12-16 | 再開されました | H.C. Wainwright | Buy |
| 2020-09-08 | 開始されました | BofA Securities | Buy |
| 2020-07-07 | 開始されました | SunTrust | Buy |
| 2019-08-26 | 開始されました | H.C. Wainwright | Buy |
| 2018-11-14 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-11-09 | ダウングレード | Guggenheim | Buy → Neutral |
| 2018-10-10 | 開始されました | Guggenheim | Buy |
| 2018-06-20 | 開始されました | BofA/Merrill | Buy |
| 2017-11-15 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2017-06-22 | 再開されました | Jefferies | Buy |
| 2016-11-01 | ダウングレード | Wedbush | Outperform → Neutral |
| 2016-10-19 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2015-12-04 | 開始されました | Wells Fargo | Outperform |
| 2015-10-23 | 再開されました | Jefferies | Buy |
| 2013-05-03 | 開始されました | BioLogic Equity Research | Sell |
| 2011-02-23 | 繰り返されました | JMP Securities | Mkt Outperform |
| 2010-07-29 | 繰り返されました | Wedbush | Outperform |
| 2009-10-19 | 開始されました | Brean Murray | Sell |
| 2009-10-07 | 繰り返されました | Leerink Swann | Outperform |
| 2009-08-25 | 繰り返されました | JMP Securities | Mkt Outperform |
すべてを表示
Sangamo Therapeutics Inc (SGMO) 最新ニュース
Analysts Just Made A Massive Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasts - Simply Wall St
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain - BioSpace
Sangamo stock climbs 12% post-market on FDA update for ST-503 - MSN
Sangamo Therapeutics Gets FDA Clearance for Investigational NDA for Pain Treatment - Marketscreener.com
Sangamo's Novel Gene Therapy for Chronic Pain Gets FDA Clearance for Clinical Trials | SGMO Stock News - StockTitan
What is HC Wainwright's Forecast for SGMO FY2024 Earnings? - MarketBeat
FY2028 Earnings Forecast for SGMO Issued By HC Wainwright - MarketBeat
Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Sangamo Therapeutics (NASDAQ:SGMO) Price Target Raised to $9.00 at Barclays - MarketBeat
Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces challenges, opportunities - Investing.com Canada
Sangamo: Q3 Earnings Snapshot - Marketscreener.com
Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates - MSN
Earnings call: Sangamo Therapeutics reports progress in gene therapies By Investing.com - Investing.com Australia
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Sangamo Therapeutics reports progress in gene therapies - Investing.com India
Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
SGMOSangamo Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Sangamo Therapeutics Q3 beats propel stock 5% higher - MSN
Sangamo Therapeutics earnings beat by $0.06, revenue topped estimates - Investing.com UK
Sangamo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results - Business Wire
Sangamo Therapeutics's Earnings Outlook - Benzinga
FY2024 Earnings Forecast for SGMO Issued By HC Wainwright - Defense World
Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market EvolutionTechnavio - The Malaysian Reserve
Equities Analysts Set Expectations for SGMO FY2024 Earnings - MarketBeat
Sangamo Therapeutics (NASDAQ:SGMO) Reaches New 12-Month High on Analyst Upgrade - Defense World
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences - The Manila Times
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences - GlobeNewswire Inc.
Sangamo (SGMO) Stock Rally Continues In Pre-Market Ahead of Financial Results Release - Stocks Telegraph
Sangamo Therapeutics (SGMO) Set to Announce Quarterly Earnings on Tuesday - MarketBeat
Sangamo Therapeutics (NASDAQ:SGMO) Price Target Raised to $10.00 at HC Wainwright - MarketBeat
Vanguard Group Inc's Strategic Reduction in Sangamo Therapeutics Inc - GuruFocus.com
Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast - StockTitan
individual investors who own 55% along with institutions invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw increase in their holdings value last week - Yahoo Finance
Sangamo Therapeutics (NASDAQ:SGMO) Stock Crosses Above 200 Day Moving Average – Here’s Why - Defense World
Sangamo Therapeutics (NASDAQ:SGMO) Stock Passes Above 200 Day Moving AverageWhat's Next? - MarketBeat
Gene Therapy Market Detailed Analysis and Forecast to 2031 - InsightAce Analytic
StockWatch: Sangamo Shares Surge on Shorter Pathway for Fabry Candidate - Genetic Engineering & Biotechnology News
Fabry disease gene therapy study data enough for FDA submission - Fabry Disease News
Prime Medicine Spat with Tessera Rumbles on at ESGCT - Genetic Engineering & Biotechnology News
Booz Allen Posts Upbeat Q3 Earnings, Joins Deckers Outdoor, Saia, Boyd Gaming And Other Big Stocks Moving Higher On FridayBooz Allen Hamilton (NYSE:BAH) - Benzinga
Sangamo Therapeutics' SWOT analysis: genomic medicine stock at crossroads - Investing.com
Sangamo Therapeutics' SWOT analysis: genomic medicine stock at crossroads By Investing.com - Investing.com UK
4 Analysts Have This To Say About Sangamo Therapeutics - Benzinga
What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You - Simply Wall St
Sangamo shares jump as FDA clears faster gene therapy pathway - The Pharma Letter
Sangamo stock rallies 37% on FDA update for Fabry disease drug - MSN
Sangamo Therapeutics, Cyclacel Pharma, GE Aerospace: 3 Stocks Retailers Are Most Bullish Tuesday Afternoon - Barchart
Sangamo Therapeutics (NASDAQ:SGMO) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Traders Purchase Large Volume of Call Options on Sangamo Therapeutics (NASDAQ:SGMO) - MarketBeat
Sangamo Therapeutics Inc (SGMO) 財務データ
収益
当期純利益
現金流量
EPS
1.80%
0.42%
大文字化:
|
ボリューム (24 時間):